M.I. Monterroso

Papers

3

Total Citations

69

H-Index

2

About

M.I. Monterroso is a leading radiation oncologist whose pioneering work has fundamentally advanced stereotactic body radiotherapy (SBRT) for lung and spine tumors. Her research centers on optimizing dose escalation and delivery techniques to improve the therapeutic ratio for non-small-cell lung cancer (NSCLC) and spinal malignancies. Monterroso’s landmark 2009 study, cited 61 times, demonstrated the curative potential of robotic stereotactic radiotherapy for peripheral Stage I NSCLC, establishing a new standard for non-invasive treatment. She further pushed boundaries by investigating individualized higher doses of 70–75 Gy in five fractions, showing that dose escalation could enhance tumor control while maintaining acceptable toxicity. In spine SBRT, Monterroso’s comparative analysis of linear accelerator versus robotic (CyberKnife) platforms provided critical dosimetric insights for treating tumors near the spinal cord. Her work has directly influenced clinical protocols, enabling safer, more effective radiation delivery. With publications spanning dose optimization, fractionation schedules, and technology comparisons, Monterroso remains a key figure in refining SBRT for challenging anatomical sites, improving outcomes for patients with early-stage and metastatic cancers.

Research Focus

Key Achievements

2
H-Index
3
Papers
69
Total Citations
23
Avg Citations/Paper
🏆 Most Cited Paper
Application of Robotic Stereotactic Radiotherapy to Peripheral Stage I Non-small Cell Lung Cancer with Curative Intent
61 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 14

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago